Clinical Trials Browser

Phase 1 × Recurrence × imetelstat × Clear all

NCT00310895 2015-12-24

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Phase 1 Completed

Recurrence

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01273090 2014-01-30

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Phase 1 Completed

CNSDermatologicLymphoidSarcoma

Astrocytoma, Burkitt Lymphoma, Glioblastoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Oligodendroglioma, Recurrence, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Neoplasms, Neuroepithelial, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma